RU2008152796A - Фармацевтическая композиция для лечения вирусных инфекций и опухолевых заболеваний ингибированием укладки белков и распада белков - Google Patents

Фармацевтическая композиция для лечения вирусных инфекций и опухолевых заболеваний ингибированием укладки белков и распада белков Download PDF

Info

Publication number
RU2008152796A
RU2008152796A RU2008152796/15A RU2008152796A RU2008152796A RU 2008152796 A RU2008152796 A RU 2008152796A RU 2008152796/15 A RU2008152796/15 A RU 2008152796/15A RU 2008152796 A RU2008152796 A RU 2008152796A RU 2008152796 A RU2008152796 A RU 2008152796A
Authority
RU
Russia
Prior art keywords
use according
chaperones
inhibit
conh
proteins
Prior art date
Application number
RU2008152796/15A
Other languages
English (en)
Russian (ru)
Inventor
Ульрих ШУБЕРТ (DE)
Ульрих ШУБЕРТ
Original Assignee
Фирологик Гмбх (De)
Фирологик Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фирологик Гмбх (De), Фирологик Гмбх filed Critical Фирологик Гмбх (De)
Publication of RU2008152796A publication Critical patent/RU2008152796A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2008152796/15A 2006-06-01 2007-06-01 Фармацевтическая композиция для лечения вирусных инфекций и опухолевых заболеваний ингибированием укладки белков и распада белков RU2008152796A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006026464.9 2006-06-01
DE102006026464A DE102006026464A1 (de) 2006-06-01 2006-06-01 Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus

Publications (1)

Publication Number Publication Date
RU2008152796A true RU2008152796A (ru) 2010-07-20

Family

ID=38626699

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008152796/15A RU2008152796A (ru) 2006-06-01 2007-06-01 Фармацевтическая композиция для лечения вирусных инфекций и опухолевых заболеваний ингибированием укладки белков и распада белков

Country Status (15)

Country Link
US (1) US20090156473A1 (fr)
EP (1) EP2029125A2 (fr)
JP (1) JP2009538881A (fr)
KR (1) KR20090048403A (fr)
CN (1) CN101453998A (fr)
AU (1) AU2007267082A1 (fr)
BR (1) BRPI0712459A2 (fr)
CA (1) CA2654276A1 (fr)
DE (1) DE102006026464A1 (fr)
IL (1) IL195611A0 (fr)
MX (1) MX2008015259A (fr)
NO (1) NO20085243L (fr)
RU (1) RU2008152796A (fr)
WO (1) WO2007138116A2 (fr)
ZA (1) ZA200810531B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
BRPI0509879A (pt) 2004-04-15 2007-10-16 Proteolix Inc compostos para inibição enzimática
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
DK1830838T3 (da) 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
BRPI0713309A2 (pt) * 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
WO2008095195A2 (fr) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Formulations lyophilisées de salinosporamide a
WO2008137780A2 (fr) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Procédés d'utilisation de composés [3.2.0]-hétérocycliques et leurs analogues pour traiter des maladies infectieuses
DE102007031397A1 (de) 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
KR20160086980A (ko) * 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2237684A2 (fr) * 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonistes pour des systèmes peptidiques antimicrobiens
KR20110011645A (ko) 2008-05-12 2011-02-08 니리어스 파마슈티컬즈, 인코퍼레이션 프로테아좀 저해제로서의 살리노스포라마이드 유도체
CA2741312C (fr) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Therapie de combinaison avec des peptides epoxycetones
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
DE102009003992A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Respirationstraktes
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP2013500265A (ja) * 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
CN102051407B (zh) * 2009-11-09 2012-12-12 中国医学科学院医药生物技术研究所 Hiv-1前体蛋白早成熟化诱导剂的筛选方法
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
KR101307132B1 (ko) * 2010-02-04 2013-09-10 이화여자대학교 산학협력단 비정상적 세포 증식 억제용 약제학적 조성물
CA2791651C (fr) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Composes pour inhibition de l'immunoproteasome
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
CN105477007B (zh) * 2014-09-15 2020-02-18 中国医学科学院药物研究所 大环内酯类药物在抗丝状病毒感染中的应用
CN105675572B (zh) * 2016-03-15 2018-09-14 四川大学华西医院 一种肺癌筛查试剂盒
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US11266675B2 (en) * 2018-04-30 2022-03-08 City University Of Hong Kong Methods of treatment of viral infection and uses of anti-HSC70 inhibitors
CN108635584B (zh) * 2018-05-22 2021-12-21 广州威溶特医药科技有限公司 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用
CN110133286A (zh) * 2019-05-20 2019-08-16 吉林大学 Hsp60基因作为靶点在脑膜炎治疗中的医用用途
CN111514299A (zh) * 2020-04-29 2020-08-11 广州中医药大学科技产业园有限公司 一种用于防治肺炎的组合物及其在制备用于防治肺炎的药物中的应用
EP4149481A1 (fr) * 2020-05-13 2023-03-22 The Regents of the University of California Thiosaccharides destinés à être utilisés dans le traitement d'une infection à coronavirus
WO2021263139A1 (fr) * 2020-06-26 2021-12-30 Duke University Procédés de traitement d'une infection à coronavirus au moyen d'inhibiteurs de hsp90

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
JP2004510826A (ja) * 2000-10-12 2004-04-08 ヴィローミクス　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ウイルス感染の治療剤
US20020160947A1 (en) * 2001-04-03 2002-10-31 Millennium Pharmaceuticals, Inc. Synergistic method for prolonging allograft survival
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20070249540A1 (en) * 2004-05-24 2007-10-25 Adonia Papathanassiu Methods for Inhibiting Proteasome and Heat Shock Protein 90
US20060252740A1 (en) * 2005-04-29 2006-11-09 Johnson Robert G Jr Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
WO2007059116A2 (fr) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Derives de geldanamycine et compositions pharmaceutiques associees

Also Published As

Publication number Publication date
MX2008015259A (es) 2009-03-26
IL195611A0 (en) 2009-09-01
KR20090048403A (ko) 2009-05-13
JP2009538881A (ja) 2009-11-12
US20090156473A1 (en) 2009-06-18
BRPI0712459A2 (pt) 2012-07-31
WO2007138116A3 (fr) 2008-05-08
WO2007138116A2 (fr) 2007-12-06
ZA200810531B (en) 2009-11-25
CA2654276A1 (fr) 2007-12-06
EP2029125A2 (fr) 2009-03-04
AU2007267082A1 (en) 2007-12-06
NO20085243L (no) 2009-02-27
DE102006026464A1 (de) 2007-12-06
CN101453998A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
RU2008152796A (ru) Фармацевтическая композиция для лечения вирусных инфекций и опухолевых заболеваний ингибированием укладки белков и распада белков
ES2272558T3 (es) Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
US20110020272A1 (en) Combination therapy for treating hepatitis viral infection
Hasobe et al. 9-(trans-2', trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and-3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity
IL217228A (en) Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP2341065A3 (fr) Inhibiteurs de sérine protéases, en particulier la HCV NS3-NS4A protéase
US11242371B2 (en) Fusion polypeptides and methods of use
EP1492545B1 (fr) Agent de traitement d'infections par flaviviridae
Zhang et al. Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells
Li et al. Targeting SARS-CoV-2 nonstructural protein 3: function, structure, inhibition, and perspective in drug discovery
JP2009526824A5 (fr)
RU2008137140A (ru) Средство для лечения инфекций, вызываемых вирусами гриппа
ES2352015T3 (es) Derivados de glutation y sus usos para el tratamiento de enfermedades virales.
Liu et al. Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors
CN114903897B (zh) 千金藤素在制备抗蜱传脑炎病毒药物中的应用
US20220054436A1 (en) Methods and compositions including protocatechuic acid crystals for the treatment of conditions caused by an enveloped virus
CN100338041C (zh) 明胶酶抑制剂与抗肿瘤剂的组合以及其应用
Haider et al. The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection
DE10361945A1 (de) Mittel zur Behandlung von Infektionen mit Coronaviridae
WO2023081198A1 (fr) Méthodes et compositions comprenant des cristaux d'acide protocatéchuique pour le traitement d'états provoqués par un virus enveloppé
CN116785295A (zh) 雷特格韦在防治新型冠状病毒感染药物中的应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110715